The latest price target for EyePoint Pharmaceuticals (NASDAQ:EYPT) was reported by HC Wainwright & Co. on December 5, 2024. The analyst firm set a price target for $22.00 expecting EYPT to rise to within 12 months (a possible 209.86% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) was provided by HC Wainwright & Co., and EyePoint Pharmaceuticals reiterated their buy rating.

There is no last upgrade for EyePoint Pharmaceuticals

There is no last downgrade for EyePoint Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of EyePoint Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for EyePoint Pharmaceuticals was filed on December 5, 2024 so you should expect the next rating to be made available sometime around December 5, 2025.

While ratings are subjective and will change, the latest EyePoint Pharmaceuticals (EYPT) rating was a reiterated with a price target of $22.00 to $22.00. The current price EyePoint Pharmaceuticals (EYPT) is trading at is $7.10, which is out of the analyst’s predicted range.